A practical reference on 生长激素轴: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
Medical personnel were routinely deployed as formed units and individual augmentees since the start of operations in Iraq and, since 2003, Reserves provided over 40% of the hospital-based personnel for operations in Afghanistan and provided the 'lead unit' for 50% of the operational tours. By 2011, across Iraq and Afghanistan, a number of reservists had been decorated and 27 had given their lives.
Erastin is a small molecule capable of initiating ferroptotic cell death. Erastin binds and activates voltage-dependent anion channels (VDAC) by reversing tubulin's inhibition on VDAC2 and VDAC3, and functionally inhibits the cystine-glutamate antiporter enzyme SLC7A11 Cells treated with erastin are deprived of cysteine and are unable to synthesize the antioxidant glutathione. Depletion of glutathione eventually leads to excessive lipid peroxidation and cell death. Erastin was first described in 2003. Its name is short for "eradicator of RAS and ST-expressing cells".
=== Death fold === Proteins with a death domain (DD), such as PIDD1, are defined by a structural framework consisting of six α-helical bundles, referred to as a 'death fold'. This structure is also present in other proteins that contain domains like the caspase recruitment domain (CARD), death effector domain (DED), pyrin domain (PYD), or combinations of these motifs (e.g., DD/CARD, DD/DED, PYRIN/CARD). These death folds facilitate homotypic protein-protein interactions (such as DD/DD or CARD/CARD), enabling the formation of large multi-protein signaling complexes. Notable examples include the apoptosome, which contains apoptotic protease-activating factor 1 (APAF1) and caspase-9, and the death-inducing signaling complex (DISC) associated with caspase-8 and members of the tumor necrosis factor receptor (TNFR) superfamily.
== Awards and honors == Wilhelm Exner Medal, 1958 Johann Josef Ritter von Precht Medal of TU wien, 1965 Erwin Schrödinger Prize of the Austrian Academy of Sciences, 1970 M.S. Tswett Chromatography Award, 1974 (first year awarded) Commemorative M.S. Tswett Medal of the U.S.S.R. Academy of Sciences, 1978 Honorary degree from the Technische Universität Berlin First-class cross of the Austrian Order for Science and Art A Street in Munich was called after her (Erika-Cremer-Straße in 81829 München)
==== Lucid dreaming ==== Lucid dreaming has been found to be associated with greater mental well-being. It also was not associated with poorer sleep quality nor with cognitive dissociation. There is also some evidence lucid dreaming therapy can help with nightmare reduction.
Sources: en.wikipedia.org
Drug development is the process of bringing a new drug to the market once a lead compound has been identified through the process of drug discovery. It includes pre-clinical research (microorganisms/animals) and clinical trials (on humans) and may include the step of obtaining regulatory approval to market the drug. Drug Development Process Discovery: The Drug Development process starts with Discovery, a process of identifying a new medicine. Development: Chemicals extracted from natural products are used to make pills, capsules, or syrups for oral use. Injections for direct infusion into the blood drops for eyes or ears. Preclinical research: Drugs go under laboratory or animal testing, to ensure that they can be used on Humans. Clinical testing: The drug is used on people to confirm that it is safe to use. FDA Review: drug is sent to FDA before launching the drug into the market. FDA post-Market Review: The drug is reviewed and monitored by FDA for the safety once it is available to the public.
== Career == In 1937, Xing returned to China. He moved to Kunming since eastern China was occupied by Japanese invaders. There, he spent some efforts on the refining of Quinine. Then Xing joined the New Fourth Army as a teacher in its military medical school. Moreover, he assisted the army to product medicine. In 1946, Xing went back to Beijing and accepted an appointment as a professor at Peking University. In the 1950s, Xing designed a new method to synthesize the chloramphenicol. During 1964–65, Xing participated in the total synthesis of bovine insulin project, co-operating with Shanghai Institutes for Biological Sciences. In 1980, Xing was elected as an academician of the Chinese Academy of Sciences. During 1981–87, Xing focused on the activation methods for the carboxyl group in the peptide synthesis, and developed related chemical reagents.
This approach, when combined with optical inspection and AI-driven image recognition, not only guarantees single-cell dispensing into the well plate or other medium but also can qualify the cell sample for quality of sample, rejecting defective cells, debris, and fragments. The development of hydrodynamic-based microfluidic biochips has been increasing over the years. In this technique, the cells or particles are trapped in a particular region for single-cell analysis, usually without application of any external force fields such as optical, electrical, magnetic, or acoustic. There is a need to explore the insights of SCA in the cell's natural state and development of these techniques is highly essential for that study. Researchers have highlighted the vast potential field that needs to be explored to develop biochip devices to suit market/researcher demands. Hydrodynamic microfluidics facilitates the development of passive lab-on-chip applications. Hydrodynamic traps allow for the isolation of an individual cell in a "trap" at a single given time by passive microfluidic transport. The number of isolated cells can be manipulated based on the number of traps in the system. The Laser Capture Microdissection technique utilizes a laser to dissect and separate individual cells, or sections, from tissue samples of interest. The methods involve the observation of a cell under a microscope, so that a section for analysis can be identified and labeled so that the laser can cut the cell. Then, the cell can be extracted for analysis.
Over time standards of refrigerator energy efficiency have been introduced and tightened, which has driven steady improvement; 21st-century refrigerators are typically three times more energy-efficient than in the 1930s. The efficiency of older refrigerators can be improved by regular defrosting (if the unit is manual defrost) and cleaning, replacing deteriorated door seals with new ones, not setting the thermostat colder than actually required (a refrigerator does not usually need to be colder than 4 °C (39 °F)), and replacing insulation, where applicable. Cleaning condenser coils to remove dust impeding heat flow, and ensuring that there is space for air flow around the condenser can improve efficiency.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
Refrigeration between 2 and 8 degrees Celsius with protection from light is the common recommendation. Many laboratories choose frozen storage at minus 20 degrees Celsius when the material will not be used soon. Repeated temperature cycling is generally avoided.